文献速递主动脉疾病

随着机构经验增加,开窗与分支腔内主动脉修复术的死亡率和主要不良事件改善

Mortality and Major Adverse Events Improve With Increased Institutional Experience for Fenestrated and Branched Endovascular Aortic Repair.
PubMed 文献 · J Endovasc Ther · 2021-12-27

单中心连续141例开窗/分支腔内主动脉修复术患者按时间三分位分组比较,2015年至2019年2月组较2002—2010年组手术时间、对比剂用量和估计失血量减少,1年和3年生存率提高,主要不良事件从51.1%降至25.5%。

要点

  • 总30天死亡率为6.3%,T1为10.6%、T2为6.3%、T3为2.1%(p=0.09)。
  • 1年和3年生存率T1为79%和56%、T2为89%和83%、T3为90%和90%(p=0.007)。
  • 任何主要不良事件总体36.9%,从早期51.1%、中期34.9%降至晚期25.5%(p=0.03)。

核心结论

  • 随着机构经验增加,开窗/分支腔内主动脉修复术的死亡率、主要不良事件和手术指标均有改善。
  • 作者推测技术、手术团队和术后护理经验、移植物设计和支架技术以及患者选择的进步共同促进了结局改善。

研究设计与样本

  • 本研究为单中心连续患者队列,纳入2002年至2019年2月在本机构接受开窗/分支腔内主动脉修复术的患者。
  • 共纳入141例患者(年龄74.8±8.1岁,男性83%),平均随访28.0±31.6个月。
  • 按时间三分位分为T1组(2002—2010年,n=47)、T2组(2011—2014年,n=47)和T3组(2015年至2019年2月,n=47)。

主要发现

  • 高血压比例T1为63.8%、T3为85.1%(p=0.009),糖尿病比例T1为6.4%、T3为29.7%(p=0.005),COPD比例T1为27.6%、T3为42.5%(p=0.07),卒中史比例T1为4.2%、T3为17%(p=0.07)。
  • 动脉瘤直径(65.3±11.4 mm)和范围(56.0%近肾/肾旁、22.0%IV型、22.0%I-III型)在各组间无差异。
  • 96.5%的病例植入定制移植物,每例重新植入3.4±0.7根血管。
  • 总手术时间T1为383.5±119.2分钟、T3为316.2±88.4分钟(p=0.02),对比剂用量T1为222.8±109.1 mL、T3为139.2±62.7 mL(p<0.0001),估计失血量T1为601.3±458.1 mL、T3为413.3±317.7 mL(p=0.02)。
  • 480根目标血管中467根完成血运重建(成功率97.3%),再干预率(30天13.5%,随访期34.7%)和无再干预生存率在各组间无显著差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Our objective was to evaluate temporal trends in outcomes at our institution in the context a more heterogenous application of fenestrated/branched endovascular aneurysm repair (F/BEVAR). METHODS: Patient and aneurysm characteristics, procedure details, and postoperative outcomes were collected for consecutive patients undergoing F/BEVAR between 2002 and February 2019 at our institution. Outcomes were compared between tertile 1 (T1, 2002-2010, n=47), T2 (2011-2014, n=47), and T3 (2015-February 2019, n=47). RESULTS: We included 141 patients (74.8 ± 8.1 years, 83% male) with a mean follow-up of 28.0 ± 31.6 months. Proportion of patients with hypertension (63.8% T1, 85.1% T3, p=0.009), diabetes (6.4% T1, 29.7% T3, p=0.005), chronic obstructive pulmonary disease (COPD; 27.6% T1, 42.5% T3, p=0.07), and history of stroke (4.2% T1, 17% T3, p=0.07) increased over time. Aneurysm diameter (65.3±11.4mm) and extent (56.0% juxtarenal/pararenal, 22.0% type IV, 22.0% type I-III) did not differ between groups. Custom made devices were implanted in 96.5% of cases with 3.4 ± 0.7 vessels reimplanted/case. There was a trend toward increased history of aortic surgery (p=0.008) and less custom made devices (p=0.007) in T3.Total procedure time (383.5±119.2 minutes T1, 316.2±88.4 T3, p=0.02), contrast volume (222.8±109.1 mL T1, 139.2±62.7ml T3, p<0.0001), and estimated blood loss (601.3±458.1 mL T1, 413.3±317.7 mL T3, p=0.02) decreased over time. Overall 30-day mortality was 6.3%, 10.6%-T1, 6.3%-T2, and 2.1%-T3 (p=0.09). We noted significant improvement in survival over time; 1- and 3-year survival was 79% and 56%, 89% and 83%, and 90% and 90%, for T1, T2, and T3, respectively (p=0.007). In all, 467 of 480 target vessels were revascularized (97.3% success). Reintervention rate (30-day: 13.5%, follow-up: 34.7%) and reintervention free survival was not significantly different between groups. Any major adverse event (MAE) occurred in 36.9% of patients overall with a significant decrease from early (51.1%), mid (34.9%), to late in our experience (25.5%, p=0.03). In multivariate analyses, increasing institutional experience (T3), procedure time, age, and sex were independent predictors of major adverse events. CONCLUSION: We have shown improvement in F/BEVAR outcomes including mortality, MAEs, and procedural metrics with increasing institutional experience. We postulate that a combination of advancements in technique, surgical team and postoperative care experience, graft design and stent technologies, and patient selection contributed to improvement in outcomes.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Doonan RJ, Bin-Ayeed S, Charbonneau P, et al. Mortality and Major Adverse Events Improve With Increased Institutional Experience for Fenestrated and Branched Endovascular Aortic Repair. J Endovasc Ther. 2021. PMID: 34955066. doi:10.1177/15266028211064813

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。